ZyVersa Therapeutics and Larkspur Health Acquisition Close Merger

 ZyVersa Therapeutics, a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop products for patients with renal or inflammatory diseases, and Larkspur Health Acquisition closed their business combination.

The SPAC in a subsequent 8-K filing following the shareholder vote disclosed that 99% of shares were redeemed, leaving about $1 million in trust.

However, the companies completed bridge financing offering to certain investors, pursuant to which 2,427,816 shares of Series A Convertible Preferred Stock of Old ZyVersa were automatically converted into 6,406,210 shares of Old ZyVersa common stock, and warrants to purchase 6,406,210 shares of common stock of Old ZyVersa were issued to certain investors. Immediately prior to the closing of the business combination, the Series A Bridge Shares converted into shares of the common stock of Old ZyVersa.

The SPAC also brought an $8.5 million PIPE to the deal.

ZyVersa’s common stock is expected to begin trading today on the Nasdaq under ticker symbol ZVSA.

The Benchmark Company LLC and Noble Capital Markets, Inc. are serving as financial advisors to ZyVersa, and Lowenstein Sandler LLP is serving as legal advisor to ZyVersa.

A.G.P./Alliance Global Partners, to which Manatt, Phelps & Phillips, is serving as legal advisor, is serving as the exclusive financial advisor to Larkspur. Alston & Bird is legal advisor to Larkspur. Read more.

 

Total
0
Shares
Related Posts
Read More

FG Merger Shareholders Approve iCoreConnect Deal

There is no minimum cash condition to close the deal. However, if the closing cash is less than $20 million then the sponsor has agreed to forfeit any and all dividends accrued on shares of preferred stock owned by the sponsor.